After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

In this trial, we enrolled participants 40 to 80 years of age who had early-stage Parkinson’s disease that had been diagnosed within the previous 3 years, who scored no more than 2.5 on the ...

We’re getting very close,” he added. Isomorphic Labs, the company that spun out from DeepMind in 2021, originated from AlphaFold, an AI system known for accurately predicting protein structures.

Transplanting dopamine-releasing neurons into the brain is a promising regenerative therapy for Parkinson’s disease. Two clinical trials show that it is safe, but more evidence is needed to ...

A total of 6082 patients were assigned to a trial group: 3040 to the intraosseous group and 3042 to the intravenous group. At 30 days, 137 of 3030 patients (4.5%) in the intraosseous group and 155 ...

Isomorphic Labs sets up U.S. presence, with an eye on clinical trials The Alphabet company, spun off from DeepMind, is hiring a new chief medical officer and adding an office in Cambridge ...

Isomorphic Labs sets up US presence in Cambridge, with an eye on clinical trials By Katie Palmer STAT,Updated June 17, 2025, 10:57 a.m.

Background: Multiple randomized phase II trials suggest that metastasis-directed therapy (MDT) for oligometastatic prostate cancer (PCa) improves progression-free survival, but the majority of trials ...